Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

Paul J. Hampel; Timothy G. Call; Wei Ding; Eli Muchtar; Saad S. Kenderian; Yucai Wang; Jose F. Leis; Thomas E. Witzig; Amber B. Koehler; Amie L. Fonder; Susan M. Schwager; Kari G. Rabe; Daniel L. Van Dyke; Esteban Braggio; Susan L. Slager; Neil E. Kay; Sameer A. Parikh

doi:10.1002/ajh.25690

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

Paul J. Hampel, Timothy G. Call, Wei Ding, Eli Muchtar, Saad S. Kenderian, Yucai Wang, Jose F. Leis, Thomas E. Witzig, Amber B. Koehler, Amie L. Fonder, Susan M. Schwager, Kari G. Rabe, Daniel L. Van Dyke, Esteban Braggio, Susan L. Slager, Neil E. Kay, Sameer A. Parikh

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	E57-E60
Journal	American journal of hematology
Volume	95
Issue number	3
DOIs	https://doi.org/10.1002/ajh.25690
State	Published - Mar 1 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25690

Cite this

Hampel, P. J., Call, T. G., Ding, W., Muchtar, E., Kenderian, S. S., Wang, Y., Leis, J. F., Witzig, T. E., Koehler, A. B., Fonder, A. L., Schwager, S. M., Rabe, K. G., Van Dyke, D. L., Braggio, E., Slager, S. L., Kay, N. E., & Parikh, S. A. (2020). Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. American journal of hematology, 95(3), E57-E60. https://doi.org/10.1002/ajh.25690

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia : Combination therapy to prevent ibrutinib flare. / Hampel, Paul J.; Call, Timothy G.; Ding, Wei; Muchtar, Eli; Kenderian, Saad S.; Wang, Yucai; Leis, Jose F.; Witzig, Thomas E.; Koehler, Amber B.; Fonder, Amie L.; Schwager, Susan M.; Rabe, Kari G.; Van Dyke, Daniel L.; Braggio, Esteban ; Slager, Susan L.; Kay, Neil E.; Parikh, Sameer A.

In: American journal of hematology, Vol. 95, No. 3, 01.03.2020, p. E57-E60.

Research output: Contribution to journal › Letter › peer-review

Hampel, PJ, Call, TG, Ding, W, Muchtar, E, Kenderian, SS, Wang, Y, Leis, JF, Witzig, TE, Koehler, AB, Fonder, AL, Schwager, SM, Rabe, KG, Van Dyke, DL, Braggio, E , Slager, SL , Kay, NE & Parikh, SA 2020, 'Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare', American journal of hematology, vol. 95, no. 3, pp. E57-E60. https://doi.org/10.1002/ajh.25690

Hampel, Paul J. ; Call, Timothy G. ; Ding, Wei ; Muchtar, Eli ; Kenderian, Saad S. ; Wang, Yucai ; Leis, Jose F. ; Witzig, Thomas E. ; Koehler, Amber B. ; Fonder, Amie L. ; Schwager, Susan M. ; Rabe, Kari G. ; Van Dyke, Daniel L. ; Braggio, Esteban ; Slager, Susan L. ; Kay, Neil E. ; Parikh, Sameer A. / Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia : Combination therapy to prevent ibrutinib flare. In: American journal of hematology. 2020 ; Vol. 95, No. 3. pp. E57-E60.

@article{10d5ce4a26504a9bb1006b96162f7588,

title = "Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare",

author = "Hampel, {Paul J.} and Call, {Timothy G.} and Wei Ding and Eli Muchtar and Kenderian, {Saad S.} and Yucai Wang and Leis, {Jose F.} and Witzig, {Thomas E.} and Koehler, {Amber B.} and Fonder, {Amie L.} and Schwager, {Susan M.} and Rabe, {Kari G.} and {Van Dyke}, {Daniel L.} and Esteban Braggio and Slager, {Susan L.} and Kay, {Neil E.} and Parikh, {Sameer A.}",

year = "2020",

month = mar,

day = "1",

doi = "10.1002/ajh.25690",

language = "English (US)",

volume = "95",

pages = "E57--E60",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia

T2 - Combination therapy to prevent ibrutinib flare

AU - Hampel, Paul J.

AU - Call, Timothy G.

AU - Ding, Wei

AU - Muchtar, Eli

AU - Kenderian, Saad S.

AU - Wang, Yucai

AU - Leis, Jose F.

AU - Witzig, Thomas E.

AU - Koehler, Amber B.

AU - Fonder, Amie L.

AU - Schwager, Susan M.

AU - Rabe, Kari G.

AU - Van Dyke, Daniel L.

AU - Braggio, Esteban

AU - Slager, Susan L.

AU - Kay, Neil E.

AU - Parikh, Sameer A.

PY - 2020/3/1

Y1 - 2020/3/1

UR - http://www.scopus.com/inward/record.url?scp=85076378989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076378989&partnerID=8YFLogxK

U2 - 10.1002/ajh.25690

DO - 10.1002/ajh.25690

M3 - Letter

C2 - 31788844

AN - SCOPUS:85076378989

VL - 95

SP - E57-E60

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this